Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

447
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
447
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.7K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.5K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.5K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

1.5K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.5K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

203
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
203
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotics for Pneumonia: From Evidence to Guidelines to Action.

Annals of internal medicine·2026
Same author

Balance Versus Bias: Correcting Misinformation About the 2025 ATS Community-Acquired Pneumonia Guidelines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Physician Antibiotic Prescribing Preferences in Community Acquired Pneumonia and Complicated Urinary Tract Infections: A National Discrete Choice Experiment.

Open forum infectious diseases·2026
Same author

Procalcitonin in the management of lower respiratory tract infection and sepsis.

The Journal of antimicrobial chemotherapy·2025
Same author

Hybrid Ambient Clinical Documentation and Physician Performance: Work Outside of Work, Documentation Delay, and Financial Productivity.

Journal of general internal medicine·2025
Same author

Agreement Between Telehealth and In-Person Evaluations of Patients with Acute Respiratory Infections.

Telemedicine journal and e-health : the official journal of the American Telemedicine Association·2025

Related Experiment Video

Updated: Sep 12, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.2K

MACRO SOLUTIONS TO A MICRO PROBLEM: DRUG-RESISTANT PNEUMOCOCCAL PNEUMONIA.

Joshua P Metlay1

  • 1Boston, MA.

Transactions of the American Clinical and Climatological Association
|August 7, 2025
PubMed
Summary

Antibiotic overuse fuels drug resistance in Streptococcus pneumoniae, a leading cause of pneumonia. Multidimensional interventions are crucial to optimize antibiotic use and combat rising resistance, despite vaccine advancements.

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

664
Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
08:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

30.4K

Related Experiment Videos

Last Updated: Sep 12, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.2K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

664
Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
08:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

30.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Acute respiratory infections are a major reason for urgent medical care.
  • Streptococcus pneumoniae (S. pneumoniae) is a primary bacterial cause of community-acquired pneumonia.
  • Multidrug resistance in S. pneumoniae emerged in the late 20th century, threatening standard antibiotic treatments.

Purpose of the Study:

  • To address the significant levels of antibiotic resistance in S. pneumoniae.
  • To explore strategies for reducing antibiotic overuse in patients with acute respiratory illnesses.
  • To identify multidimensional interventions targeting patients, clinicians, and health systems.

Main Methods:

  • Review of existing literature on antibiotic resistance trends in S. pneumoniae.
  • Analysis of factors contributing to antibiotic overuse.
  • Evaluation of the impact of the pneumococcal conjugate vaccine.
  • Assessment of current interventions aimed at optimizing antibiotic use.

Main Results:

  • Antibiotic overuse, in both adults and children, is a major driver of pneumococcal drug resistance.
  • The pneumococcal conjugate vaccine (introduced in 2000) reduced overall pneumococcal pneumonia incidence but did not eliminate significant antibiotic resistance.
  • Despite improvements, a substantial quality gap remains in optimizing antibiotic use.

Conclusions:

  • Reducing antibiotic overuse requires comprehensive strategies involving patients, clinicians, and healthcare systems.
  • Organizational strategies and policies are needed to optimize antibiotic prescribing for responsive acute illnesses.
  • Continued efforts are necessary to mitigate the threat of multidrug-resistant S. pneumoniae infections.